Extended Data Fig. 1: Extended data in relation to Fig. 1a–e.
From: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
a, Related to Fig. 1a. EZH2 mRNA levels within normal tissue (n = 111), or TNBC tumours resected at stage I (n = 19), stage II (n = 74), stage III (n = 19), or stage IV (n = 2). Box shows 10–90 percentiles with line at median. b, Treatment schema for all in vitro studies. c-d, Immunoblot depicting relative levels of AKT target inhibition (pPRAS40) and EZH2 target inhibition (H3K27me3) and relevant loading controls in sensitive (c) and resistant (d) cell lines from panel in Fig. 1c. Experiment was repeated at least 3 times. e, Dose dependence of cell death induced by the combination of EZH2i (tazemetostat) and AKTi (ipatasertib) measured by Incucyte Live Cell Imaging. Data for 5 μM AKTi are presented as the 72 h time point in Fig. 1d. n = 8. p *** <0.001 measured by unpaired one-tailed heteroscedastic Student’s T-test. Data are images from 8 independent wells. f, Synergy plots using Gaddum’s non-interaction model (HSA) for cells treated with AKTi (ipatasertib) and/or EZH2i (tazemetostat).
